Attached files
file | filename |
---|---|
8-K - LIBERATOR MEDICAL HOLDINGS, INC. | g25500e8vk.htm |
Exhibit 99.1
Liberator Medical to Restate Financial Results for Non-Cash Adjustments
No Impact on Reported Revenues, Operating Income, Operating Expenses, Total Assets or Cash
Position
STUART, Fla., Dec. 10, 2010 (GLOBE NEWSWIRE) Liberator Medical Holdings, Inc. (OTCBB:LBMH)
today announced that it would restate the Companys previously issued unaudited financial
statements for the interim periods ended December 31, 2009, March 31, 2010, and June 30, 2010, to
comply with certain accounting guidance that became effective for the Company on October 1, 2009.
The changes are to non-cash items and will not affect the Companys reporting income, operating
income, operating expenses, total assets, or cash position for the three quarters to be restated.
The restatement resulted from the Companys reevaluation of the accounting treatment of certain
convertible notes issued by the Company to a single investor in May and October 2008. The notes
were converted into the Companys common stock in May and October 2010, respectively. The notes
contained embedded anti-dilution provisions that could have led to adjustments in the conversion
price of the notes if the Company had issued additional shares of common stock or like securities
at a price per share less than both the conversion price then in effect and $0.75, which the
Company did not do at any time after the notes were issued.
Previously, the Company had concluded that these embedded anti-dilution provisions were indexed to
the Companys own stock under applicable accounting guidance and that changes in guidance effective
for the Company commencing October 1, 2009, did not change the accounting treatment of the embedded
conversion features. After reevaluating the accounting guidance and the Companys accounting
treatment of the embedded conversion features during its year-end audit process, the Company
concluded that the embedded anti-dilution provisions were not indexed to the Companys own stock
and, therefore, were embedded derivative financial liabilities that require bifurcation and
separate accounting.
Accordingly, the Company determined that it should have recorded a cumulative effect adjustment to
the opening balance of retained earnings on October 1, 2009, and that thereafter it was required to
adjust these embedded derivatives, as long as they existed, to fair value at each balance sheet
date or interim period, recognize the changes in fair value as a non-cash charge or benefit to
earnings, and record changes below income from operations in the Companys statements of
operations.
Mark Libratore, the Companys President and CEO, commented, Our philosophy has been to report all
of the Companys financial data very conservatively and comply with all generally accepted
accounting principles. The Companys financial position remains strong and we are pleased that all
of the convertible notes relating to these changes no longer exist.
The following is a summary of the effects that the restatement adjustments will have on the
Companys unaudited financial statements for each of the interim periods to be restated. The
effects of the restatements presented are estimates that are subject to change based upon the
Companys final analysis and review of the adjustments.
As of and for the three months ended December 31, 2009 (dollars in thousands, except per share
amounts):
Cumulative | ||||||||||||||||
As | Effect | Current | ||||||||||||||
Previously | Adjustment | Period | As | |||||||||||||
Reported | as of 10/1/2009 | Effect | Restated | |||||||||||||
Balance Sheet Data: |
||||||||||||||||
Current Assets |
$ | 12,697 | $ | | $ | | $ | 12,697 | ||||||||
Total Assets |
16,986 | | | 16,986 | ||||||||||||
Current Liabilities |
11,860 | 5,224 | 5,271 | 22,355 | ||||||||||||
Total Liabilities |
12,601 | 5,224 | 5,271 | 23,096 | ||||||||||||
Cumulative | ||||||||||||||||
As | Effect | Current | ||||||||||||||
Previously | Adjustment | Period | As | |||||||||||||
Reported | as of 10/1/2009 | Effect | Restated | |||||||||||||
Additional Paid in Capital |
11,820 | (390 | ) | | 11,430 | |||||||||||
Accumulated Deficit |
(7,418 | ) | (4,834 | ) | (5,271 | ) | (17,523 | ) | ||||||||
Total Equity (Deficit) |
$ | 4,385 | $ | (5,224 | ) | $ | (5,271 | ) | $ | (6,110 | ) | |||||
For the three months ended December 31, 2009 | ||||||||||||
As Previously | Current | As | ||||||||||
Reported | Period Effect | Restated | ||||||||||
Statement of Operations Data: |
||||||||||||
Income from Operations |
$ | 1,160 | $ | | $ | 1,160 | ||||||
Other Income (Expense): |
||||||||||||
Interest Expense |
(243 | ) | (173 | ) | (416 | ) | ||||||
Change in fair value of derivative liabilities |
| (5,099 | ) | (5,099 | ) | |||||||
Total Other Income (Expense) |
(240 | ) | (5,271 | ) | (5,511 | ) | ||||||
Net Income (Loss) |
$ | 854 | $ | (5,271 | ) | $ | (4,417 | ) | ||||
Basic Earnings (Loss) per Share |
$ | 0.03 | $ | (0.16 | ) | $ | (0.13 | ) | ||||
Diluted Earnings (Loss) per Share |
$ | 0.02 | $ | (0.15 | ) | $ | (0.13 | ) |
As of and for the three and six months ended March 31, 2010 (dollars in thousands, except per share
data):
Cumulative | ||||||||||||||||
As | Effect | |||||||||||||||
Previously | Adjustment as | Current | As | |||||||||||||
Reported | of 10/1/2009 | Period Effect | Restated | |||||||||||||
Balance Sheet Data: |
||||||||||||||||
Current Assets |
$ | 20,796 | $ | | $ | | $ | 20,796 | ||||||||
Total Assets |
26,524 | | | 26,524 | ||||||||||||
Current Liabilities |
12,697 | 5,224 | 5,503 | 23,424 | ||||||||||||
Total Liabilities |
14,405 | 5,224 | 5,503 | 25,132 | ||||||||||||
Additional Paid in Capital |
19,291 | (390 | ) | | 18,901 | |||||||||||
Accumulated Deficit |
(7,161 | ) | (4,834 | ) | (5,503 | ) | (17,498 | ) | ||||||||
Total Equity (Deficit) |
$ | 12,119 | $ | (5,224 | ) | $ | (5,503 | ) | $ | 1,392 | ||||||
For the three months | For the six months | |||||||||||||||||||||||
ended March 31, 2010 | ended March 31, 2010 | |||||||||||||||||||||||
As | Current | As | Current | |||||||||||||||||||||
Previously | Period | As | Previously | Period | As | |||||||||||||||||||
Reported | Effect | Restated | Reported | Effect | Restated | |||||||||||||||||||
Statement of Operations Data: |
||||||||||||||||||||||||
Income from Operations |
$ | 360 | $ | | $ | 360 | $ | 1,521 | $ | | $ | 1,521 | ||||||||||||
Other Income (Expense): |
||||||||||||||||||||||||
Interest Expense |
(229 | ) | (173 | ) | (402 | ) | (472 | ) | (345 | ) | (817 | ) | ||||||||||||
Change in fair value of derivative liabilities |
| (59 | ) | (59 | ) | | (5,158 | ) | (5,158 | ) | ||||||||||||||
Total Other Income (Expense) |
(226 | ) | (232 | ) | (458 | ) | (466 | ) | (5,503 | ) | (5,969 | ) | ||||||||||||
Net Income (Loss) |
$ | 256 | $ | (232 | ) | $ | 24 | $ | 1,111 | $ | (5,503 | ) | $ | (4,392 | ) | |||||||||
Basic Earnings (Loss) per Share |
$ | 0.01 | $ | (0.01 | ) | $ | 0.00 | $ | 0.03 | $ | (0.16 | ) | $ | (0.13 | ) | |||||||||
Diluted Earnings (Loss) per Share |
$ | 0.01 | $ | (0.01 | ) | $ | 0.00 | $ | 0.02 | $ | (0.15 | ) | $ | (0.13 | ) |
As of and for the three and nine months ended June 30, 2010 (dollars in thousands, except per share
data):
Cumulative | ||||||||||||||||
As | Effect | |||||||||||||||
Previously | Adjustment as | Current | As | |||||||||||||
Reported | of 10/1/2009 | Period Effect | Restated | |||||||||||||
Balance Sheet Data: |
||||||||||||||||
Current Assets |
$ | 22,167 | $ | | $ | | $ | 22,167 | ||||||||
Total Assets |
28,436 | | | 28,436 | ||||||||||||
Current Liabilities |
9,898 | 5,224 | (2,869 | ) | 12,253 | |||||||||||
Total Liabilities |
10,531 | 5,224 | (2,869 | ) | 12,886 | |||||||||||
Additional Paid in Capital |
24,274 | (390 | ) | 4,813 | 28,697 | |||||||||||
Accumulated Deficit |
(6,364 | ) | (4,834 | ) | (1,944 | ) | (13,142 | ) | ||||||||
Total Equity (Deficit) |
$ | 17,905 | $ | (5,224 | ) | $ | (2,869 | ) | $ | 15,550 | ||||||
For the three months | For the nine months | |||||||||||||||||||||||
ended June 30, 2010 | ended June 30, 2010 | |||||||||||||||||||||||
As | Current | As | Current | |||||||||||||||||||||
Previously | Period | As | Previously | Period | As | |||||||||||||||||||
Reported | Effect | Restated | Reported | Effect | Restated | |||||||||||||||||||
Statement of Operations Data: |
||||||||||||||||||||||||
Income from Operations |
$ | 942 | $ | | $ | 942 | $ | 2,461 | $ | | $ | 2,461 | ||||||||||||
Other Income (Expense): |
||||||||||||||||||||||||
Interest Expense |
(150 | ) | (139 | ) | (289 | ) | (621 | ) | (484 | ) | (1,105 | ) | ||||||||||||
Change in fair value of derivative liabilities |
| 3,698 | 3,698 | | (1,459 | ) | (1,459 | ) | ||||||||||||||||
Total Other Income (Expense) |
(142 | ) | 3,559 | 3,417 | (607 | ) | (1,944 | ) | (2,551 | ) | ||||||||||||||
For the three months | For the nine months | |||||||||||||||||||||||
ended June 30, 2010 | ended June 30, 2010 | |||||||||||||||||||||||
As | Current | As | Current | |||||||||||||||||||||
Previously | Period | As | Previously | Period | As | |||||||||||||||||||
Reported | Effect | Restated | Reported | Effect | Restated | |||||||||||||||||||
Net Income (Loss) |
$ | 798 | $ | 3,559 | $ | 4,357 | $ | 1,908 | $ | (1,944 | ) | $ | (36 | ) | ||||||||||
Basic Earnings (Loss) per Share |
$ | 0.02 | $ | 0.08 | $ | 0.10 | $ | 0.05 | $ | (0.05 | ) | $ | (0.00 | ) | ||||||||||
Diluted Earnings (Loss) per Share |
$ | 0.02 | $ | 0.06 | $ | 0.08 | $ | 0.04 | $ | (0.04 | ) | $ | (0.00 | ) |
Stay up-to-date with current events by visiting Liberator Medicals website at
www.liberatormedical.com or by joining the Companys E-Mail Alert List. Join by clicking the
following link www.LBMH-IR.com
About Liberator Medical Holdings, Inc.
Liberator Medical Holdings, Inc.s subsidiary, Liberator Medical Supply, Inc., established the
Liberator brand as a leading national direct-to-consumer provider of quality medical supplies to
Medicare-eligible seniors. An Exemplary Provider(TM) accredited by The Compliance Team, its unique
combination of marketing, industry expertise and customer service has demonstrated success over a
broad spectrum of chronic conditions. Liberator is recognized for offering a simple, reliable way
to purchase medical supplies needed on a regular, ongoing, repeat-order basis, with the convenience
of direct billing to Medicare and private insurance. Liberators revenue primarily comes from
supplying products to meet the rapidly growing requirements of general medical supplies, diabetes
supplies, catheters, ostomy supplies and mastectomy fashions. Liberator communicates with patients
and their doctors on a regular basis regarding prescriptions and supplies. Customers may purchase
by phone, mail or internet, with repeat orders confirmed with the customer and shipped when needed.
Safe Harbor Statement
Certain statements in this press release that are not historical, but are forward-looking, are
subject to known and unknown risks and uncertainties which may cause the Companys actual results
in future periods to be materially different from any future performance that may be suggested in
this press release. Such risks and uncertainties may include, but are not limited to regulatory
limitations on the medical industry in general, fluctuations in customer demand and commitments,
fluctuation in quarterly results, introduction of new services and products, commercial acceptance
and viability of new services and products, pricing and competition, reliance upon subcontractors
and vendors, the timing of new technology and product introductions, the risk of early obsolescence
of our products and the other factors listed under Risks and Uncertainties in our annual report
on Form 10-K for the fiscal year ended September 30, 2009, and our other filings with the
Securities and Exchange Commission. We assume no obligation to update the information contained in
this news release.
CONTACT: | Wall Street Resources, Inc. Individual Investor Relations Contact: Gerald Kieft 772-219-7525 LiberatorIR@wallstreetresources.net http://www.wallstreetresources.net Littlebanc Advisors, LLC Institutional Investor Contact: Lyn Davis 561-948-3005 ld@littlebanc.com www.littlebanc.com |
Source: Liberator Medical Holdings, Inc.